Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
ConditionParkinson's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoston Scientific Corporation
About this trial
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Eligibility criteria
Qualifiers
Meets criteria established in locally applicable Vercise System Direction for Use
At least 18 years old
Disqualifiers
Meets any contraindication in the Vercise System locally applicable Directions for Use
Trial design
Treatments tested in this trial
- Deep Brain Stimulation (DBS)
Treatment groups
1,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov